PreciseDx to Present at the 2022 San Antonio Breast Cancer Symposium

Company to share research on how a novel AI-digital test enriches recurrence score risk prediction in breast cancer 

NEW YORK, December 1, 2022 –  PreciseDx, a leading AI company that leverages the analysis of morphology features from histology slides to provide more precise, patient-specific risk information, today announced that it will present at the 2022 San Antonio Breast Cancer Symposium. The poster session, “A Novel AI-Digital Test with Automated Approach for Grading and Phenotyping Breast Cancer Enriches Recurrence Score Risk Prediction in an Oncotype Evaluated Cohort,” will highlight the results of using the PreciseDx AI-enabled risk prediction platform, when combined with Oncotype Dx recurrence scores, to enhance overall risk discrimination for recurrence in early-stage breast cancer patients.  

WHO: PreciseDx

WHAT: Join PreciseDx for a poster presentation, “A Novel AI-Digital Test with Automated Approach for Grading and Phenotyping Breast Cancer Enriches Recurrence Score Risk Prediction in an Oncotype Evaluated Cohort,” that showcases its recent research. 

The 2022 San Antonio Breast Cancer Symposium, which provides state-of-the-art information on breast cancer research. The in-person conference takes place from December 6-10, 2022. 

WHEN: Wednesday, December 7, 2022 from 5:00pm to 6:15pm CT

WHERE: The Henry B. Gonzalez Convention Center in San Antonio, TX

MEDIA: PreciseDx is available for in-person briefings by request via email to precisedx@0to5.com.

About PreciseDx

PreciseDx is a leading AI company that leverages the analysis of morphology features from histology slides to provide more precise, patient-specific risk information. PreciseDx’s Morphology Feature Array™ allows clinical teams to have access to unmatched insights and accurate, actionable intelligence for disease state characterization to determine the best treatment for each patient. To learn more about PreciseDx, visit https://precisedx.ai/